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Abstract 
Introduction: Women with polycystic ovary syndrome (PCOS) frequently develop metabolic complications. Among the newly found 
factors responsible for metabolic disorders, adropin seems to be of a great significance. 
Material and methods: In total 134 women aged 17–45 years were enrolled. The PCOS group consisted of 73 women, diagnosed on the 
basis of Executive Committee of the European Society of Human Reproduction and Embryology — American Society for Reproduc-
tive Medicine (ESHRE-ASRM) criteria. All PCOS women presented phenotype A of PCOS. The control group consisted of 61 women 
with regular menstrual cycles, matched for nutritional status. All women underwent anamnesis, physical examination, anthropometric 
measurements, abdominal and transvaginal ultrasound, and dual-energy X-ray absorptiometry (DXA). Serum adropin levels were deter-
mined by ELISA. Biochemical [fasting glucose and insulin, oral glucose tolerance test, lipid and sex hormone-binding globulin (SHBG)] 
and hormonal (testosterone, androstenedione, luteinizing hormone, follicle-stimulating hormone and oestradiol) measurements were 
performed. Insulin resistance indices [(Homeostasis Model Assessment for Insulin Resistance (HOMA-IR), Quantitative Insulin Sensitivity 
Check Index (QUICKI), Matsuda] and free androgen index (FAI) were calculated according to the standard formula. 
Results: Serum adropin levels were lower in the PCOS group (0.475  ±  0.200 vs. 0.541  ±  0.220, p = 0.069), but the results were not statisti-
cally significant. Positive correlations among adropin and androstenedione levels were observed in the PCOS group (r = 0.27, p = 0.025). 
Conclusions: Women with PCOS have a different metabolic profile in comparison to women without this syndrome. We did not observe 
a statistically significant difference in adropin concentration between the PCOS and the healthy control group. Therefore, more studies 
regarding adropin in PCOS are needed. (Endokrynol Pol 2019; 70 (2): 151–156)
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Introduction 
Polycystic ovary syndrome (PCOS) is the most common 
endocrinopathy in the group of reproductive-aged 
women, with a prevalence of 6–25%, depending on the 
diagnostic criteria used [1]. This is a complex syndrome 
consisting of menstrual disorders, hyperandrogenism 
and ovarian dysfunction. Although metabolic disorders 
are not included in the diagnostic criteria, they are 
an integral part of this syndrome [2]. The number of 
studies on new peptides crucial in the pathogenesis 
of metabolic disorders is rapidly increasing. Among 
the new potential factors responsible for metabolic 
disorders, adropin seems to be of a great significance. 
Adropin is a 76-amino acid peptide hormone (4499.9 
Da) coded by the energy homeostasis associated gene 
(Enho). It was first isolated in 2008 by Kumar et al. from 
hepatic cells [3]. Animal model studies showed that 
Enho gene expression was regulated by nutrition, but 
the exact mechanism of the action was not fully under-
stood. Mice fed on a high-fat and low-carbohydrate diet 
had rapid increase in Enho gene expression and higher 
adropin serum levels. On the other hand, animals 
fed on low-fat and high-carbohydrate diet presented 
lower adropin serum levels [4]. Additionally, mice with 
knock-out adropin gene developed fat growth, insulin 
resistance (IR), and dyslipidaemia. Furthermore, adro-
pin administered parenterally reduced food intake, 
leading to weight loss in obese mice [4]. In another 
animal study on rats with diet-induced obesity (DIO) 
and IR, Gio et al. showed that adropin administration 
to DIO mice enhanced glucose tolerance, ameliorated 
IR, and promoted preferential use of carbohydrate over 
fat in fuel selection [5]. Based on these reports, it has 
been concluded that adropin could play an important 
role in maintaining energy homeostasis and regulating 
lipid metabolism, thus preventing dyslipidaemia, IR, 
and impaired glucose tolerance (IGT) [3–6]. 
Human studies in gestational diabetes, type 2 
diabetes mellitus (DM 2), and nonalcoholic fatty liver 
disease (NAFLD) patients noted decreased plasma 
adropin levels [7–9]. The results of research in obese 
adults showed that adropin levels were also lower in 
these individuals [10]. On the other hand, the results 
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To conduct biochemical analyses, venous blood samples (15 ml) 
were collected from the women in the follicular phase of menstrual 
cycle in the morning following an overnight fast. Hormonal and 
biochemical analyses were performed, then plasma was collected 
and frozen at –70°C until further assayed. 
Serum adropin level was determined by ELISA (Peninsula Labo-
ratories International, San Carlos, California, USA) using a BioTek 
EL 800 analyser. 
Biochemical measurements: fasting glucose and insulin, two-hour 
blood glucose and insulin level after glucose overload (2-h OGTT), 
lipid and sex hormone-binding globulin (SHBG) levels and hor-
monal measurements: total testosterone (T), androstenedione, 
luteinising hormone (LH), follicle-stimulating hormone (FSH), and 
oestradiol levels were also performed. IR indices (HOMA, Quan-
titative Insulin Sensitivity Check Index [QUICKI], Matsuda) were 
calculated according to the standard formulas. The free androgen 
index (FAI) was calculated as the ratio of the total testosterone level 
to SHBG level multiplied by 100.
Statistics analysis
EPIINFO Ver. 7.1.1.14 was used for statistical analysis. Distribution 
of parameters was determined using Kolmogorov-Smirnov test. For 
all groups, expected values (x), medians (M), range from minimum 
to maximum (min–max), standard deviations (SD), and lower and 
upper quartiles (25Q–75Q) were measured. Verification of equation 
of mean parameters in independent groups was performed by 
Student t-test in case of parametric and Mann Whitney U-test in 
nonparametric distribution. In tables, depending on the distribution 
of variables, the parameters are expressed as the mean  ±  standard 
deviation (normal distribution) or as the median and the lower and 
upper quartile (distribution deviated from the normal). For selected 
pairs of parameters, linear regression analysis was performed by 
calculating Pearson’s correlation coefficient.
Results
Anthropometric parameters
Anthropological characteristics of the groups are 
presented in Table I. PCOS patients were older than 
non-PCOS. There were no significant differences in 
BMI between groups. Statistically significant differences 
(0.836 ± 0.097 vs. 0.802 ± 0.087, p < 0.05) in waist-to-hip 
ratio (WHR) and android distribution of fat (32.4 ± 10 
vs. 27.1 ± 9.2, p < 0.05) were observed, while there were 
no statistically significant differences in waist circumfer-
ence and total body fat between groups. 
Metabolic results
Biochemical and hormonal characteristics of the patients 
are given in Table II. Subjects with PCOS had lower HDL 
cholesterol levels (55.1 ± 20.6 vs. 67 ± 20.8, p < 0.05) and 
higher TG levels (119 ± 65.3 vs. 77.8 ± 37.8, p < 0.001). 
There were no statistically significant differences in 
total cholesterol and LDL cholesterol levels between 
groups. PCOS women had higher fasting (9.15 ± 7.08 
vs. 6.11 ± 6.21, p < 0.05) and 2-h OGTT (71.8 ± 62.1 
vs. 38.1 ± 23.7, p < 0.001) serum insulin levels. There 
were no statistically significant differences in fasting 
and 2-h OGTT glucose levels. Statistically significant dif-
ferences in IR indices were observed — HOMA-IR was 
higher (1.94 ± 1.56 vs. 1.23 ± 1.51, p < 0.001), QUICKI 
of studies of obese children are contradictory [11, 12]. 
Decreased plasma adropin levels were also observed 
in patients with acute myocardial infarction (AMI) and 
coronary atherosclerosis [8, 13].
There are four reports available on adropin in 
women with PCOS. The authors concluded that the 
serum adropin levels were lower in the PCOS group 
in all of them [14–17]. One study showed a negative 
correlation between adropin and fasting insulin levels, 
Homeostasis Model Assessment for Insulin Resistance 
(HOMA-IR), total cholesterol, very-low-density lipopro-
tein cholesterol (VLDL), and triglycerides (TG) [14]. On 
the other hand, Kume et al. demonstrated that adropin 
levels were negatively correlated with fasting insulin 
and glucose levels, HOMA-IR, body mass index (BMI), 
total cholesterol, low-density lipoprotein cholesterol 
(LDL), and TG. In this study the relations between adro-
pin and tumour necrosis factor alpha (the level of which 
was higher in PCOS) was also examined. However, no 
correlation between these two parameters was found 
[15]. Intal and Sen also demonstrated lower adropin in 
a PCOS group [16, 17].
The aims of our study were to assess serum adropin 
levels in PCOS patients in comparison to women with-
out menstrual disturbances, matched for nutritional 
status (BMI), and to assess correlations between adropin 
serum levels and metabolic and hormonal markers. 
Material and methods
Patients
A total of 134 women aged 17–45 years were enrolled. The PCOS 
group consisted of 73 women hospitalised in the Department of 
Endocrinology, Diabetes, and Isotope Therapy in Wroclaw. All 
PCOS women fulfilled three Rotterdam criteria, including bio-
chemical hyperandrogenism. Exclusion criteria included all other 
endocrinopathies associated with hyperandrogenism. The non-
PCOS group consisted of sixty-one women with regular menstrual 
cycles, recruited among the students and patients with simple 
obesity without hormonal disorders. Both groups were matched 
for nutritional status. 
Methods
PCOS was diagnosed on the basis of Executive Committee of 
the European Society of Human Reproduction and Embryology 
— American Society for Reproductive Medicine (ESHRE-ASRM) 
criteria (Rotterdam criteria), including three of the following: oligo- 
or anovulation, biochemical hyperandrogenism, and polycystic 
ovaries on ultrasound [18, 19]. All patients underwent anamnesis 
and physical examination as well as transvaginal and abdominal 
ultrasound. Anthropometric measurements (weight, height, 
waist and hip circumferences) were performed in all women. 
BMI was calculated as the ratio of weight (kg) to height squared 
(m2). Waist-to-hip ratio (WHR) was calculated as the ratio of waist 
circumference (cm) to hip circumference (cm). Android (abdomi-
nal) obesity was diagnosed when WHR was greater than or equal 
to 0.8. Abdominal ultrasound examination was performed in all 
subjects to assess the hepatosteatosis. Body composition (android 
and gynoid distribution) was measured with dual-energy X-ray 
absorptiometry (DXA). 
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Table I. Anthropological characteristics of the groups
PCOS patients (n = 73) Non-PCOS patients (n = 61) p
Age [years] 24.3 ± 4.823.0 
(20.0–27.0)
29.2 ± 6.4 
28.0 (23.0–34.0) < 0.001
Weight [kg] 76.2 ± 19.0 
75.0 (61.0–89.0)
69.6 ± 13.3 
65.0 (60.0–77.0) 0.034*
BMI [kg/m2] 27.5 ± 6.4 
26.4 (22.3–31.6)
25.3 ± 4.7 
24.2 (22.5–26.6) 0.078*
Waist circumference [cm] 88.7 ± 16.9 
84.0 (75.5–101.5)
84.5 ± 12.4 
80,0 (76.0–92.0) 0.208*
WHR 0.836 ± 0.097 
0.829 (0.763–0.896)
0.802 ± 0.087 
0.793 (0.750–0.857) 0.036*
Body fat (%) 34.8 ± 6.8 
35.1 (30.9–40.0)
33.1 ± 6.5 
33.3 (27.8–38.2) 0.143
#
Android fat distribution (%) 32.4 ± 10.0 
33.2 (25.2–40.7)
27.1 ± 9.2 
25.8 (19.4–33.7) 0.002
#
Gynoid fat distribution (%) 37.8 ± 5.9 
37.7 (34.6–41.3)
37.2 ± 5.8 
37.1 (33.1–41.8) 0.596
#
PCOS — polycystic ovary syndrome; BMI — body mass index; WHR — waist-to-hip ratio; p — statistical significance; * — difference between medians,  
# — difference between mean ± SD 
Table II. Metabolic and hormonal characteristics of the groups
PCOS patients (n = 73) Non-PCOS patients (n = 61) p
TC [mg/dL] 191.3 ± 35.5
192.0 (165.5–210.0)
180.2 ± 38.5
179.0 (160.0–202.0) 0.090
#
LDL-C [mg/dL] 112.3 ± 33.7
111.5 (85.0–128.5)
106.6 ± 35.5
106.5 (83.0–129.0) 0.341
#
HDL-C [mg/dL] 55.1 ± 20.6
52.0 (40.5–65.0)
67.0 ± 20.8
65.0 (48.0–84.5) 0.001
#
TG [mg/dL] 119.0 ± 65.3
96.5 (70.5–154.5)
77.8 ± 37.8
675 (51.5–94.5) < 0.001*
FBG [mg/dL] 84.4 ± 6.9
86.0 (79.0–89.0)
79.4 ± 20.0
82.0 (76.0–90.0) 0.244
*
2h OGTT [mg/dL] 100.0 ± 26.5
95.0 (86.0–112.0)
91.5 ± 25.5
87.0 (74.0–107.0) 0.067
#
FIns [µIU/mL] 9.15 ± 7.08
7.08 (2.80–14.30)
6.11 ± 6.21
4.91 (2.00–7.01) 0.007*
2h Ins [µIU/mL] 71.8 ± 62.1
49.5 (30.0–93.9)
38.1 ± 23.7
33.1 (23.6–50.1) 0.001*
HOMA-IR 1.94 ± 1.56
1.31 (0.55–3.02)
1.23 ± 1.51
0.80 (0.40–1.36) 0.001*
QUICKI 0.372 ± 0.054
0.367 (0.324–0.426)
0.397 ± 0.052
0.384 (0.365–0.449) 0.008
#
Matsuda index 7.89 ± 6.08
5.39 (3.41–11.36)
11.9 ± 6.8
10.8 (6.7–17.3) 0.001
#
Total T [ng/mL] 0.750 ± 0.325
0.680 (0.520–0.920)
0.356 ± 0.133
0.330 (0.240–0.440) < 0.001*
SHBG [nmol/L] 33.4 ± 21.6
27.0 (18.3–38.0)
59.6 ± 30.8
54.3 (36.8–75.1) < 0.001*
FAI (%) 9.36 ± 4.00
8.70 (6.83–11.22)
2.54 ± 1.43
2.17 (1.49–3.21) < 0.001*
Androstenedione [ng/mL] 5.72 ± 2.24
4.97 (4.35–7.37)
2.63 ± 1.02
2.56 (1.82–3.30) < 0.001*
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(0.372 ± 0.054 vs. 0.397 ± 0.052, p < 0.05) and Mat-
suda index (7.89 ± 6.08 vs. 11.9 ± 6.8, p < 0.001) were 
lower in PCOS women. Also noted were significantly 
higher total testosterone (0.75 ± 0.325 vs. 0.356 ± 0.133, 
p < 0.001), androstenedione (5.72 ± 2.24 vs. 2.63 ± 1.02, 
p < 0.001), and FAI levels (9.36 ± 4 vs. 2.54 ± 1.43, 
p < 0.001) in PCOS patients. Women with PCOS had 
a higher prevalence of hepatic steatosis, but this result 
was not statistically significant. Alanine and aspartate 
transaminase (AlAT and AspAT) levels were statisti-
cally significantly higher (22.7 ± 8.5 vs. 19.5 ± 7.4 and 
23.9 ± 13.4 vs. 18.7 ± 10.2, respectively, p < 0.05) in 
PCOS women. 
Serum adropin levels were lower in PCOS group 
(Tab. III, Fig. 1) but this result was not statistically 
significant (0.475 ± 0.2 vs. 0.541 ± 0.22, p = 0.0691). In 
addition, the positive correlation among adropin and 
AlAT (r = 0.236, p = 0.046) as well as adropin and an-
drostenedione (r = 0.27, p = 0.025) levels were observed 
in the PCOS group. However, no other significant cor-
relations between adropin levels and metabolic and 
hormonal markers were observed. 
Discussion
Among the new factors responsible for metabolic 
disorders, adropin seems to be of great significance. 
Table II. Metabolic and hormonal characteristics of the groups
PCOS patients (n = 73) Non-PCOS patients (n = 61) p
LH [mIU/mL] 11.7 ± 5.9
10.3 (7.5–14.6)
5.95 ± 3.16
5.16 (4.00–6.91) < 0.001*
FSH [mIU/mL] 5.78 ± 1.45
5.94 (5.14–6.83)
5.99 ± 2.37
5.79 (4.41–8.08) 0.766*
LH/FSH 2.06 ± 1.04
1.89 (1.26–2.65)
1.31 ± 1.33
0.93 (0.68–1.34) < 0.001
#
E2 [pg/mL] 64.7 ± 45.0
53.9 (44.5–67.8)
98.3 ± 95.3
71.1 (28.2–117.0) 0.262
#
Steatohepatitis Yes — 44 patients 
No — 29 patients
Yes — 27 patients 
No — 34 patients 0.064
#
AlAT 22.7 ± 8.5
20.0 (17.0–26.5)
19.5 ± 7.4
19.0 (15.0–22.0) 0.028
#
AspAT 23.9 ± 13.4
18.5 (14.0–31.5)
18.7 ± 10.2
16.0 (13.0–20.0) 0.025*
PCOS — polycystic ovary syndrome; TC – total cholesterol, LDL-C — low-density lipoprotein cholesterol; HDL-C — high-density lipoprotein cholesterol; TG — triglyce-
ride; FBG — fasting blood glucose; 2h OGTT — 2h blood glucose after glucose overload; FIns — fasting insulin; 2h Ins — 2-h blood insulin after glucose overload, 
HOMA-IR — homeostatic model assessment-insulin resistance index; QUICKI — quantitative insulin sensitivity check index; T — testosterone; SHBG — sex hormone 
binding globulin; FAI — free androgen index; LH — luteinising hormone; LH/FSH — luteinising hormone-to-follicle stimulating hormone ratio; E2 — oestradiol;  
AlAT — alanine aminotransferase; AspAT — aspartate aminotransferase; p — statistical significance; * — difference between medians; # — difference between 
mean ± SD 
Table III. Serum adropin levels in groups
PCOS patients (n = 73) Non-PCOS patients (n = 61) p
Adropin [ng/ml] 0.475 ± 0.200
0.447 (0.370–0.542)
0.541 ± 0.220
0.487 (0.424–0.595) 0.069*
PCOS — polycystic ovary syndrome; p — statistical significance; * — difference between medians
Figure 1. Serum adropin levels in patients with polycystic 
ovary syndrome (PCOS) and without PCOS (non-PCOS). 
p — statistical significance; SEM — standard error of the mean; 
SD — standard deviation
 Mean
Mean ± SEM
Mean ± SD
p = 0.0691
0.8
0.7
0.6
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0.4
0.3
0.2
PCOS non-PCOS
A
d
ro
p
in
 [
n
g
/m
L
]
155
Endokrynologia Polska 2019; 70 (2)
O
R
IG
IN
A
L
 P
A
P
E
R
PCOS is typically associated with metabolic com-
plications; therefore, it might be possible that the 
levels of peptides involved in the aetiopathogenesis 
of metabolic disorders might be changed in women 
with PCOS [20, 21].
In our study serum adropin levels were lower in 
PCOS patients, but this result was not statistically sig-
nificant (p = 0.069), which is probably due to the small 
sample size. In four available studies on adropin in 
PCOS women, Kume, Yildrim, Inal, and Sen presented 
significantly lower adropin concentrations in women 
with PCOS compared to a control group. In all of these 
studies, serum adropin level was negatively correlated 
with IR indices [14–17]. 
The results of our study did not show the correla-
tions between adropin levels and fasting and 2-h glu-
cose and insulin levels. There was also no correlation 
with IR indices, including HOMA-IR.
Studies on animals have suggested a possible adro-
pin effect on the carbohydrate metabolism. Kumar, 
in his first study on animals, showed that mice with 
the knock-out gene of adropin presented impaired 
glucose tolerance (IGT), which could suggest the role 
of adropin in the development of IR and DM2 [4]. In 
another study, Aydin demonstrated higher amounts 
of adropin in pancreas, liver, brain, cerebellum, and 
kidneys of rats with diabetes induced by streptozoto-
cin (STZ) [22]. However, Akciar et al., in recent study 
in rats with STZ-induced diabetes, showed that the 
adropin levels were significantly lower in those with 
diabetes. They demonstrated that the adropin adminis-
tration caused a significant decrease of fasting glucose 
level, HOMA-IR, and HbA1c. The authors suggested 
that adropin could improve glucose metabolism and 
insulin sensitivity by inhibition the production of in-
flammatory cytokines [23].
Wu et al. confirmed the observation that patients 
with DM2 had significantly lower adropin levels [8]. 
The results of the studies on pregnant women with 
GDM were consistently showing lower serum adropin 
levels in this group [8, 24, 25]. However, Beigi et al. did 
not show any correlations between adropin and fasting 
glucose levels in GDM women [24]. Similarly, Lian et 
al. did not find these correlations in patients with heart 
insufficiency [26]. On the other hand, Butler et al. dem-
onstrated a negative correlation between adropin and 
fasting glucose levels in obese patients [10]. A similar 
correlation was found by Kume in PCOS patients [15]. 
Kume and Yildrim showed also negative correlations 
between adropin and HOMA-IR and fasting insulin 
levels in PCOS patients [14, 15]. 
Thus, the results of recent studies are contradic-
tory. In our study, women in both groups did not have 
elevated glucose levels. Therefore, it could be a reason 
for the lack of correlation. Further studies are needed 
to determine the impact of adropin on glucose and 
insulin metabolism. 
There was no correlation between serum adropin 
levels and lipids in our studies. No correlation was 
also found in Lian’s study of patients with heart insuf-
ficiency [26] and Beigi’s report in GDM women [24]. 
The animal studies suggested that adropin had 
an impact on fat metabolism. Akciar et al. demonstrated 
that adropin administered parenterally reduced the 
total cholesterol, TG, and LDL cholesterol levels and 
increased HDL cholesterol levels in mice with DM 
[23]. Butler, in his study in obese patients, reported that 
serum adropin levels were negatively correlated with 
TG and LDL cholesterol levels and positively correlated 
with HDL cholesterol and FFA levels [10]. Kume et al. 
also demonstrated negative correlation between adro-
pin and total cholesterol, LDL cholesterol, and TG in 
PCOS patients [15]. Similar correlations were found by 
Butler et al. in obese patients. They also showed a posi-
tive correlation between adropin and HDL cholesterol 
[10]. Yildrim showed a negative correlation between 
adropin and total cholesterol, TG, and VLDL cholesterol 
in PCOS women [14]. 
The results of recent studies are not always consis-
tent. However, they show that adropin has some effects 
on lipid metabolism, but further studies are needed to 
clarify the issue. 
In the present analysis, we found correlation be-
tween serum adropin levels and androstenedione, but 
not with testosterone. There were few findings showing 
correlations between adropin and androgens. Kume 
did not find any correlation between adropin and an-
drogens [15]. Therefore, it seems to be worthwhile to 
expand our study.
In the present research, we found that serum adro-
pin levels were correlated neither with BMI nor with 
any other anthropometric parameters. These results 
were confirmed in other studies [9, 24, 25]. On the 
other hand, Lian et al. showed that the serum adropin 
levels were positively correlated with BMI in patients 
with heart insufficiency [26]. However, most studies 
showed a negative correlation between adropin and 
BMI [10, 12–14]. Butler et al. also demonstrated that the 
adropin serum levels were negatively correlated with 
BMI in obese patients. Moreover, they observed that the 
adropin levels increased after Roux-en-Y gastric bypass, 
peaking three months after surgery [10].
Moreover, it was shown that adropin levels were de-
pendent on dietary preferences in female patients. The 
serum adropin levels were positively correlated with 
fat intake and negatively correlated with carbohydrate 
intake in women [27]. Animal studies conducted by 
Kumar confirmed these observations [4]. 
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Based on these studies, it seems that adropin plays 
a role in energy homeostasis and possibly protects 
against obesity and IR by regulating fat and carbohy-
drate metabolism. 
The limitations of this study need to be considered. 
Firstly, our groups were not in the same age range. PCOS 
women were younger, hence metabolic disorders might 
not have been advanced enough. A major limitation is 
also the small sample size; according to power analysis, 
the power of our test was 60% (sample size calculation 
- 157 patients in one group). The IR indices (HOMA-IR, 
QUICKI, Matsuda) were used to diagnose IR. The “gold 
standard” is the euglycemic metabolic clamp; however, 
this test is difficult to perform in outpatients, so we 
resigned from this method. It is also worth considering 
the determination of adropin after glucose loading and 
observing its variable postprandial concentrations. The 
strength of our study is that our PCOS group was 
homogenous according to PCOS criteria — all PCOS 
patients were hyperandrogenic (phenotype A). 
Conclusions
Serum adropin levels were lower in the PCOS group, but 
this result was not statistically significant. In addition, 
a positive correlation between adropin and androstene-
dione levels was observed in the PCOS group. However, 
no other significant correlations between adropin levels 
and metabolic and hormonal markers were observed. 
Adropin seems to be a protective factor against IR and 
DIO. It would be valuable to conduct further studies 
to assess the impact on, and relation of, adropin with 
metabolic disorders typically associated with PCOS. 
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